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Abstract
In order to selectively block nuclear factor κB (NF-κB)-
dependent signal transduction in angiogenic endothelial cells,
we constructed an αvβ3 integrin specific adenovirus encoding
dominant negative IκB (dnIκB) as a therapeutic gene. By virtue
of RGD modification of the PEGylated virus, the specificity of
the cell entry pathway of adenovirus shifted from coxsacki-
adenovirus receptor dependent to αvβ3 integrin dependent
entry. The therapeutic outcome of delivery of the transgene into
endothelial cells was determined by analysis of cellular
responsiveness to tumor necrosis factor (TNF)-α. Using real
time reverse transcription PCR, mRNA levels of the cell
adhesion molecules E-selectin, vascular cell adhesion molecule
(VCAM)-1 and intercellular adhesion molecule (ICAM)-1, the
cytokines/growth factors IL-6, IL-8 and vascular endothelial
growth factor (VEGF)-A, and the receptor tyrosine kinase Tie-2
were assessed. Furthermore, levels of ICAM-1 protein were
determined by flow cytometric analysis. RGD-targeted
adenovirus delivered the dnIκB via αvβ3 to become functionally
expressed, leading to complete abolishment of TNF-α-induced
up-regulation of E-selectin, ICAM-1, VCAM-1, IL-6, IL-8, VEGF-
A and Tie-2. The approach of targeted delivery of dnIκB into
endothelial cells presented here can be employed for diseases
such as rheumatoid arthritis and inflammatory bowel disease
where activation of NF-κB activity should be locally restored to
basal levels in the endothelium.
Introduction
Microvascular endothelial cells are active participants in a vari-
ety of diseases, including cancer [1] and chronic inflammation
such as rheumatoid arthritis [2]. In inflammatory reactions,
endothelial cells facilitate transmigration of leukocytes by
expression of cell adhesion molecules such as E-selectin, vas-
cular cell adhesion molecule (VCAM-1) and intercellular adhe-
sion molecule (ICAM-1), as well as production of cytokines
and chemokines [3]. Inflammatory mediators can also, either
directly or indirectly, promote angiogenesis. Moreover, several
observations suggest that angiogenesis and inflammation pro-
ceed in a co-ordinated fashion and sustain one another during
chronic inflammatory diseases and in cancer growth [4]. Thus,
their active roles in the pathophysiology of disease, together
with their easy accessibility in the blood, makes endothelial
cells attractive target cells for therapy.
Nuclear factor κB (NF-κB)/Rel transcription factors represent
a ubiquitously expressed protein family that modulates the
expression of genes involved in diverse cellular functions, such
CAR = coxsacki-adenovirus receptor; Ct = threshold cycle; dn, dominant negative; FCS = fetal calf serum; HA = hemagglutinin; HUVEC = Human 
umbilical vein endothelial cell; ICAM = intercellular adhesion molecule; IL = interleukin; NF-κB = nuclear factor κB; PBS = phosphate-buffered saline; 
PEG = polyethylene glycol; RADpep = cyclic RAD peptide c(RADf(-S-acetylthioacetyl)K); RGDpep = cyclic RGD peptide c(RGDf(-S-acetylth-
ioacetyl)K); RT-PCR = reverse transcription polymerase chain reaction; TNF = tumor necrosis factor; VCAM = vascular cell adhesion molecule; VEGF 
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as stress response, innate and adaptive immune reactions,
and apoptosis [5-8]. In endothelial cells, NF-κB is activated by
inflammatory cytokines, bacterial lipopolysaccharides, oxi-
dized low-density lipoprotein, advanced glycation end prod-
ucts, platelet-derived growth factor, and hypoxia/
reoxygenation, among others. Rheumatoid arthritis, inflamma-
tory bowel disease and other chronic inflammatory processes
have been associated with elevated levels of endothelial NF-
κB [9-13].
A dominant negative form of IκB (dnIκB) that contains serine-
to-alanine mutations at amino acids 32 and 36 blocks endog-
enous IκB phosphorylation and subsequent proteosome-
mediated degradation, thereby inhibiting NF-κB mediated
gene expression [14]. To achieve selective gene transfer of
dnIκB into endothelial cells, adenovirus can be used as a vec-
tor. Infection by adenovirus is initiated by the high affinity bind-
ing of the carboxy-terminal 'knob' part of the fiber protein to
coxsacki-adenovirus receptor (CAR), thereby limiting its infec-
tion specificity to CAR-positive cells. In a previous study, we
showed that PEGylation of the adenovirus and subsequent
conjugation with anti-E-selectin antibody as a homing ligand
coupled onto the distal functional group of polyethylene glycol
(PEG) could selectively deliver a reporter gene into activated
endothelial cells in vivo. The modulated virus-target cell inter-
action took place via recognition of E-selectin on activated
endothelium by the homing ligand, thereby evading the endog-
enous CAR-based tropism of the virus [15]. In the present
study, we constructed an RGD-modified, αvβ3 integrin spe-
cific adenovirus encoding dnIκB as a therapeutic gene to
block NF-κB-dependent signal transduction in endothelial
cells. Integrin specificity of RGD-modified adenovirus with
respect to its gene transfer and transgene expression was
evaluated by western blot analysis. Pharmacological effective-
ness of delivery and expression of the transgene into endothe-
lial cells was studied using real time reverse transcription (RT)-
PCR and flow cytometric analysis of pro-inflammatory and pro-
angiogenic gene expression profiles in tumor necrosis factor
(TNF)-α activated endothelial cells.
Materials and methods
Chemicals and proteins
RGD and control peptides
The cyclic RGD-peptide c(RGDf(-S-acetylthioacetyl)K) and
the RAD analogue c(RADf(-S-acetylthioacetyl)K), hereafter
referred to as RGDpep and RADpep, respectively, were pre-
pared by Ansynth (Roosendaal, The Netherlands). This RGD-
pep was previously conjugated to a humanized antibody that
does not recognize any epitope relevant for the cells under
study (hereafter referred to as RGD-protein). RGD conjuga-
tion provided the protein with αvβ3 integrin specificity [16].
Production of knob5
The knob domains of adenovirus5 fibers were expressed in
Escherichia coli with amino-terminal His6 tags, using the
pQE30 expression vector (Qiagen, Hilden, Germany) [17].
Knob5 was purified on Ni-nitrilotriacetic acid agarose columns
(Qiagen) and dialyzed against PBS. The ability of knob5 to
form homotrimers was verified by SDS-PAGE of boiled and
unboiled samples. The concentration of the purified knob5
was determined by the Bradford protein assay (Bio-Rad, Her-
cules, CA, USA) using bovine serum albumin as the standard.
Cells
Endothelial cells
Human umbilical vein endothelial cells (HUVECs) were
obtained from the Endothelial Cell Facility UMCG (Groningen,
The Netherlands). Primary isolates were cultured on 1% gela-
tin-precoated tissue culture flasks (Costar, The Netherlands)
at 37°C under 5% CO2/95% air. The endothelial cell culture
medium consisted of RPMI 1640 supplemented with 20%
heat inactivated FCS, 2 mM L-glutamine, 5 U/ml heparin, 100
U/ml penicillin, 100 µg/ml streptomycin, and 50 µg/ml
endothelial cell growth factor supplement extracted from
bovine brain. Upon confluence, cells were detached from the
surface by trypsin/EDTA (0.5/0.2 mg/ml in PBS; GibcoTM,
Paisley, Scotland, UK) and split at a 1:3 ratio. For the experi-
ments described, HUVECs were used up to passage four.
Viruses
The recombinant replication-deficient adenovirus encoding
dominant negative form of IκB under control of the cytomega-
lovirus (CMV) promoter, hereafter referred to as AddnIκB, con-
tains a hemagglutinin (HA)-tagged super-repressor IκB. This
super-repressor IκB has serine-to-alanine mutations in resi-
dues 32 and 36, which inhibit its phosphorylation and proteo-
some-mediated degradation [14]. Virus was grown on
HEK293 cells and purified in Hepes/sucrose buffer, pH 8.0,
according to conventional double CsCl gradient centrifuga-
tion methods, and the number of viral particles was calculated
from the optical density at 260 nm (OD260). AdLacZ, which
contains the E. coli β-galactosidase gene, was grown and
purified as described above and used as a control virus.
Standard plaque assays were performed to determine the viral
particles (vp)/plaque forming unit ratio, which were found to be
15 for both viruses.
Chemical conjugation of adenovirus
Conjugation reactions were performed as reported previously
[15]. In brief, an aliquot of heterobifunctional polyethylene gly-
col (PEG) linker (3.4 kDa) with a N-hydroxysuccinimide ester
and vinyl sulfone group at each end of the molecule (NEKTAR
Therapeutics, Huntsville, AL, USA) dissolved in dimethyl for-
mamide (DMF) (100 mg/1 ml DMF) was added slowly to the
virus (1 × 1012  viral particles) in a ratio of 105:1 moles
PEG:viral particles. The reaction mixture was protected from
light and gently mixed for 1.5 hours at 4°C. After the purifica-
tion using a PD-10 column (Amersham Biotech, Uppsala,
Sweden), PEGylated virus was directly used in the following
coupling reaction with either RGDpep or RADpep. RGDpepAvailable online http://arthritis-research.com/content/8/1/R32
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or RADpep dissolved in an acetonitrile-water mixture (1:4) at a
concentration of 10 mg/ml was added dropwise to the
PEGylated virus in the molar ratio of 105:1. After the addition
of 25 µl of a freshly prepared 1 M hydroxylamine solution to
deprotect the thiol group of the peptide, the mixture was
reacted for four hours at 4°C under gentle mixing. Unreacted
reagents were removed by dialysis (DispoDialyzers 300 KD
MWCO, Spectrum Laboratories, Rancho Dominguez, CA,
USA) against Hepes/sucrose buffer (pH 8.0) at 4°C. Initial
studies showed that in the PD-10 column purification proce-
dure, the first 80% of the peak containing PEGylated virus that
eluted from the column was free from contamination with
unconjugated PEG, and that the dialysis procedure did not
lead to loss of conjugated virus. Therefore, we collected the
initial 80% of PEGylated virus that eluted from the PD-10 col-
umn and used the factor of 0.8 to calculate the final number of
viral particles of each preparation. The final virus preparation
was collected and stored at -80°C in small aliquots until use.
Transduction protocol
For the transduction experiments, HUVECs were plated at
12,500 cells/cm2  in 25 cm2-tissue culture flasks (Costar,
Cambridge, MA, USA) for western blotting, or in 6-well tissue
culture plates (Costar) for flow cytometric analysis and real
time RT-PCR, and cultured overnight before starting the exper-
iments. The various viral vectors diluted in Dulbecco's modi-
fied Eagle's medium without FCS were added to the HUVECs
and incubated for 90 minutes at 37°C. The medium was then
replaced by normal endothelial cell culture medium and cells
were incubated for another 24 hours to allow transgene pro-
duction. In the case of competition experiments, cells were
incubated with RGD-protein (50 µg/ml), recombinant knob5
(20 µg/ml), or both for 30 minutes at 4°C prior to the addition
of viruses.
Western blot analysis of dnIκB in HUVECs
HUVECs were infected with AddnIκB, AddnIκB-PEG-RGD or
AddnIκB-PEG-RAD (3,000 vp/cell) as described. After
another 24 hours of culturing, cells were detached from the
surface by trypsin/EDTA treatment, lysed in cell culture lysis
reagent (Promega Corporation, Madison, WI, USA) and soni-
cated twice for five seconds. After centrifugation for ten min-
utes at 10,000g, cleared cell lysates were collected and
protein content was determined using the Bradford protein
assay reagent (Bio-Rad Laboratories, Hercules, CA, USA),
using bovine serum albumin as the standard. Samples were
then mixed 1:1 with 2 × SDS sample buffer, boiled for 5 min-
utes, and 30 µg was loaded on SDS-PAGE 10% acrylamide
gels followed by blotting to nitrocellulose membranes (Bio-
Rad Laboratories). The dnIκB protein was detected using a
rabbit anti-HA-tag antibody (sc805; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), while both endogenous IκB and
dnIκB were detected using a rabbit anti-IκB antibody (sc847;
Santa Cruz Biotechnology). Blots were blocked in blocking
buffer (5% non-fat drymilk in PBS) for two hours, incubated for
one hour with primary antibody diluted in blocking buffer
1:200 (sc805) or 1:250 (sc847) and subsequently with
horseradish peroxidase-conjugated swine anti-rabbit antibody
(Dako, Glostrup, Denmark) diluted in blocking buffer 1:2,000.
Detection was performed using ECL detection reagents
(Amersham Corp., Arlington Heigths, IL, USA) according to
the manufacturer's protocol.
RNA isolation and real time RT-PCR analysis
HUVECs were infected with AddnIκB and AddnIκB-PEG-
RGD at 7,500 vp/cell as described. After another 24 hours of
culturing, cells were activated with 100 ng/ml TNF-α (Boe-
hringer, Ingelheim, Germany), or left resting. Total RNA was
isolated 24hours after activation using the Absolutely RNA
Microprep Kit (Stratagene, Amsterdam, The Netherlands)
according to the protocol of the manufacturer. RNA yield
(OD260) and purity (OD260/280) was measured using a ND-
1000 UV- Vis Spectrophotometer (NanoDrop Technologies,
Rockland, DE, USA). One µg total cellular RNA was subse-
quently used for the synthesis of first strand cDNA using
SuperScript III RNase H- Reverse Transcriptase (Invitrogen,
Breda, The Netherlands) in 20 µl final volume containing 250
ng random hexamers (Promega) and 40 units RNase OUT
inhibitor (Invitrogen). After RT-reaction, cDNA was diluted with
distilled water to 100 µl. The following exons overlapping prim-
ers and minor groove binder (MGB) probes used for real time
RT-PCR were purchased as Assay-on-Demand from Applied
Biosystems (Nieuwekerk a/d IJssel, The Netherlands): house-
keeping gene GAPDH (assay ID Hs99999905_m1), endothe-
lial cell marker CD31 (PECAM-1 (platelet endothelial cell
adhesion molecule 1), Hs00169777_m1), E-selectin
(Hs00174057_m1), VCAM-1 (Hs00365486_m1), ICAM-1
(Hs00164932_m1), IL-6 (Hs00174131_m1), IL-8
(Hs00174103_m1), Hs00173626_m1 (hVEGF-A), and
Hs00176096 (hTie-2). The final concentration of primers and
MGB probes in TaqMan PCR MasterMix (Applied Biosystems,
Foster City, CA, USA) for each gene was 900 nM and 250 nM,
respectively. As a control, RNA samples not subjected to
reverse transcriptase were analyzed to exclude unspecific sig-
nals arising from genomic DNA. Those samples consistently
showed no amplification signals.
TaqMan real time RT-PCR was performed in an ABI PRISM
7900HT Sequence Detector (Applied Biosystems). Amplifica-
tion was performed using the following cycling conditions: 2
minutes at 50°C, 10 minutes at 95°C, and 40 to 45 two-step
cycles of 15 seconds at 95°C and 60 s at 60°C. Triplicate real
time RT-PCR analyses were executed for each sample, and
the obtained threshold cycle (Ct) values were averaged.
According to the comparative Ct method described in the ABI
manual, gene expression was normalized to the expression of
the housekeeping gene GAPDH, yielding the ∆Ct value. The
average ∆Ct value obtained from resting HUVECs was then
subtracted from the average ∆Ct value of each corresponding
sample subjected to TNF-α stimulation, yielding the ∆∆CtArthritis Research & Therapy    Vol 8 No 1    Ogawara et al.
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Figure 1
Human umbilical vein endothelial cells (HUVECs) express functional dnIκB protein upon AddnIκB infection as demonstrated by western blot analy- sis and gene expression analysis by real time RT-PCR Human umbilical vein endothelial cells (HUVECs) express functional dnIκB protein upon AddnIκB infection as demonstrated by western blot analy-
sis and gene expression analysis by real time RT-PCR. (a) HUVECs were incubated with AddnIκB for 90 minutes at 37°C, in the absence or pres-
ence of 20 mg/ml recombinant viral knob, as described in Materials and methods. Cells were subsequently washed and incubated for another 24 
hours. After preparation of cellular protein homogenate, western blotting was performed to detect IκB total protein (upper panel), the hemagglutinin-
tagged transgene dnIκB (middle panel), and actin to control for protein loading (lower panel). (b) Non-infected (solid bar) and AddnIκB (open bar) or 
AdLacZ (gray bar) transduced HUVECs were activated with tumor necrosis factor (TNF)-α (100 ng/ml) for 24 h before real time RT-PCR was per-
formed on mRNA isolated from each respective HUVEC incubation. Data were normalized to untreated, non-activated control HUVECs arbitrarily set 
at 1. Results are expressed as the mean ± standard deviation (n = 3). Asterisks indicate p < 0.05 compared with respective control cells without 
activation with TNF-α (TNF-α (-)). ICAM, intercellular adhesion molecule; ns, not significant; VCAM, vascular cell adhesion molecule; VEGF, vascular 
endothelial growth factor.Available online http://arthritis-research.com/content/8/1/R32
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value. The gene expression level, normalized to the house-
keeping gene, and relative to the control sample, was calcu-
lated by 2-∆∆Ct. Data were normalized to untreated, non-
activated control HUVECs arbitrarily set at 1.
In our preliminary analysis, we used CD31 as a housekeeping
gene since it is constitutively expressed in HUVECs and its
expression is NF-κB-independent (JM Kuldo and G Molema,
unpublished data. The outcome for all genes studied remained
the same as when GAPDH was used as the housekeeping
gene. We therefore regarded GAPDH as a good housekeep-
ing gene for use in the experimental conditions used in this
study.
Flow cytometric analysis of ICAM expression
HUVECs were infected with AddnIκB (7,500 vp/cell), AdLacZ
(7,500 vp/cell) and AddnIκB-PEG-RGD at different amounts
of vp/cell as described. After another 24 hours of culturing,
cells were activated with 100 ng/ml TNF-α (Boehringer) or left
resting. Cells were detached from the surface by trypsin/EDTA
4 hours after activation and resuspended in PBS with 5%
FCS. Cells were subsequently centrifuged at 200 × g, after
which the cell pellets were incubated for 1 hour at 37°C with
100 µl of primary antibody. The following primary antibodies
were used: mouse anti-human ICAM (5/3-2.1, kindly provided
by Dr MA Gimbrone Jr, Boston, MA, USA), mouse anti-human
CD31 (M0823, Dako) to detect CD31 as a standard marker
for endothelial cells, and mouse anti-rat ICAM-1 (1A29, kindly
provided from Dr M Miyasaka, Osaka Univ., Osaka, Japan) as
an iso-type control. After washing, cells were incubated for
one hour with 100 µl rat anti-mouse F(ab')2-FITC (F0313,
Dako). After extensive washing, cells were fixed with 0.5% for-
malin in PBS. Flow cytometric analysis was performed within
24 hours after fixation using a Coulter Epics-Elite flow cytom-
eter (Coulter Electronics, Hialeah, FL, USA). Data were ana-
lyzed using Winlist (version 3D; verity Software House,
Topsham, ME, USA) and WinMDI (version 2.8; The Scripps
Research Institute, La Jolla, CA, USA) software.
Statistical analysis
Statistical significance of differences was evaluated by means
of the two-sided Student's t test, assuming equal variances.
Differences were considered to be significant when p < 0.05.
Results
Effectiveness of the virally delivered dnIκB protein
For the functional validation of the virus itself, we first infected
HUVECs with AddnIκB. Western blotting experiments
showed that the transgene was successfully expressed upon
infection. Furthermore, pre-incubation with recombinant knob
strongly inhibited the transduction of AddnIκB while not affect-
ing the expression level of endogenous IκB (Figure 1a). Nei-
ther non-infected nor AdLacZ-infected HUVECs expressed
the transgene (data not shown). Several genes that are char-
acteristic for the inflammatory responses in endothelial cells
Figure 2
DnIκB expression in human umbilical vein endothelial cells (HUVECs)  affects cellular responsiveness to tumor necrosis factor (TNF)-α activa- tion, leading to diminished expression of intercellular adhesion mole- cule-1 protein as determined by flow cytometry DnIκB expression in human umbilical vein endothelial cells (HUVECs) 
affects cellular responsiveness to tumor necrosis factor (TNF)-α activa-
tion, leading to diminished expression of intercellular adhesion mole-
cule-1 protein as determined by flow cytometry. HUVECs were infected 
with AddnIκB (7,500 vp/cell) or AdLacZ (7,500 vp/cell). After 24 hours 
of culturing, cells were activated with 100 ng/ml TNF-α, or left resting. 
Cells were detached 4 hours after activation and subjected to flow 
cytometric analysis. Non-activated, resting HUVECs (solid line with 
gray area); TNF-α activated HUVECs (bold solid line); TNF-α activated 
HUVECs infected with AddnIκB (solid line); and TNF-α activated 
HUVECs infected with AdLacZ control virus (dotted line). FITC, fluoros-
cein isothiocyanate. MIF, mean fluorescence intensity.
Table 1
mRNA levels of the genes studied upon tumor necrosis factor-α 
activation
Gene product Fold increase
CD31 0.8 ± 0.1
E-selectin 3,778 ± 200
Vascular cell adhesion molecule-1 637 ± 12
Intercellular adhesion molecule -1 245 ± 7.0
IL-6 5.3 ± 0.2
IL-8 9.9 ± 0.5
Tie-2 3.6 ± 0.1
Vascular endothelial growth factor-A 3.1 ± 0.1
Data are expressed as basal gene expression levels in non-stimulated 
human umbilical vein endothelial cells set at 1. Results are expressed 
as the mean ± standard deviation (n = 3).Arthritis Research & Therapy    Vol 8 No 1    Ogawara et al.
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contain functional NF-κB binding sites in their promoter
regions, leading to enhanced transcription upon NF-κB activa-
tion [13]. We therefore determined the pharmacological
effects of dnIκB transgene expression in HUVECs by analysis
of mRNA levels of typical cell adhesion molecules, cytokines
and some other angiogenesis-related genes in HUVECs upon
TNF-α stimulation (Figure 1b). TNF-α stimulation enhanced
mRNA levels of all genes investigated in untreated HUVECs,
ranging from 3,778-fold for E-selectin to 3.1-fold for VEGF-A,
except for the mRNA level of CD31, the expression of which
was non-responsive to TNF-α stimulation (Table 1). This tran-
scriptional induction was completely abolished in dnIκB
expressing HUVECs activated with TNF-α. In contrast, trans-
duction with the control virus AdLacZ did not affect the TNF-
α induced up-regulation of cell adhesion molecules and the
angiogenesis-related genes encoding VEGF-A and Tie-2. In
AdLacZ infected HUVECs, IL-6 and IL-8 mRNA levels exhib-
ited higher and lower increases, respectively, upon TNF-α
stimulation compared to uninfected HUVECs, which may be a
result of viral infection per se. Yet, TNF-α driven increases in
mRNA levels of these genes was completely abolished in
dnIκB expressing HUVECs. The effect of AddnIκB or AdLacZ
infection per se on basal mRNA expression in the absence of
TNF-α was within 20% for all genes investigated. This implies
that viral infection does not influence basal expression under
the conditions studied and, furthermore, that the observed
non-responsiveness of dnIκB expressing HUVECs to an
inflammatory stimulus was due to NF-κB blockade, and not
due to viral infection itself. In all conditions, >80% of the dnIκB
expressing HUVECs remained viable, as assessed microscop-
ically as well as by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) viability assay (data not shown).
To further confirm the inhibitory effects of the transgene on
expression levels of NF-κB driven proteins, we determined the
expression level of the transmembrane protein ICAM-1 (Figure
2), mRNA levels of which were shown to be silenced by the
transgene (Figure 1b). TNF-α stimulation markedly induced
the expression of ICAM-1 protein on the membrane of the
endothelial cells. This expression was completely inhibited in
HUVECs infected with AddnIκB prior to TNF-α stimulation,
while no inhibitory effect was observed after pre-infection with
control virus (AdLacZ). In contrast, the constitutively
expressed endothelial gene CD31 was not affected by dnIκB
(data not shown), thereby corroborating other observations
that CD31 expression is NF-κB independent (JM Kuldo and G
Molema, unpublished data). From these data, we concluded
that the transgene employed could be functionally expressed
in the primary endothelial cells without compromising cell via-
bility.
RGD-PEG modification endows adenovirus with αv 
integrin specific infectivity and transgene expression
We next confirmed the change in the entry pathway of RGD-
retargeted adenovirus into HUVECs from a CAR-dependent
to an αvβ3 integrin-dependent mode. Western blotting analy-
sis of HA-tagged dnIκB (Figure 3) demonstrated that non-
modified AddnIκB exhibited efficient transduction upon infec-
tion to HUVECs. The presence of exogenously added RGD-
protein did not affect this transduction, suggesting that the
entry pathway of non-modified virus is exclusively CAR-
dependent. On the other hand, the transduction of HUVECs
by AddnIκB-PEG-RGD was significantly inhibited by the pres-
ence of RGD-protein but not by recombinant knob5, while
AddnIkB-PEG-RAD showed no transduction at all. These
results strongly suggest that RGD modification successfully
endowed adenovirus with αv integrin specific infectivity to
endothelial cells, and that peptide modification per se was not
responsible for directing the tropism of the virus.
RGD-PEG modified adenovirus can transfer a 
functionally active dnIκB gene into endothelial cells
To study whether chemically modified AddnIκB exerted thera-
peutic potential for interference of inflammatory and ang-
Figure 3
AddnIκB-PEG-RGD infected human umbilical vein endothelial cells (HUVECs) express dnIκB in a knob-independent, RGD-dependent manner AddnIκB-PEG-RGD infected human umbilical vein endothelial cells (HUVECs) express dnIκB in a knob-independent, RGD-dependent manner. 
HUVECs were incubated with either non-modified AddnIκB, AddnIκB-PEG-RGD or AddnIκB-PEG-RAD (3,000 vp/cell) for 90 minutes, in the 
absence or presence of either 20 mg/ml recombinant viral knob or 50 mg/ml RGD-protein or both, as described in Materials and methods. Cells 
were subsequently washed and incubated for another 24 h. After preparation of cellular protein homogenate, western blotting was performed to 
detect the hemagglutinin-tagged transgene, and actin to control for protein loading.Available online http://arthritis-research.com/content/8/1/R32
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iogenic processes, we evaluated mRNA levels of the same set
of genes investigated to study functionality of the non-modified
virus.
Figure 4 shows that TNF-α driven expression of all pro-inflam-
matory and pro-angiogenic genes was completely abolished in
HUVECs infected with the RGD-PEG modified virus. Moreo-
ver, AddnIκB-PEG-RGD exhibited a similar inhibitory effect on
gene expression as the non-modified virus (Figure 1b).
mRNA data demonstrating that the chemically modified RGD-
PEG-adenovirus could transfer functionally active dnIκB gene
into endothelial cells were confirmed by the analysis of ICAM-
1 protein expression (Figure 5). The larger the number of viral
particles of AddnIκB-PEG-RGD used for the infection, the
higher the percentage of ICAM-1dim cells (cells that do not
express significant levels of ICAM-1 protein) upon TNF-α acti-
vation, ranging from 6% for HUVECs transduced at 1.5 × 103
vp/cell to 27% for HUVECs transduced at the highest number
of viral particles, 15 × 103 vp/cell. AddnIκB-PEG-RAD did not
show any significant inhibitory effect on ICAM-1 protein
expression upon TNF-α stimulation (data not shown), which is
in line with the absence of dnIκB protein expression in cells
exposed to this control virus (see western blot analysis shown
in Figure 3).
Discussion
NF-κB is a transcription factor that controls the expression of
cytokines, chemokines and endothelial cell adhesion mole-
cules to facilitate leukocyte movement from the blood stream
into the underlying tissue [18,19]. NF-κB controls the vicious
circle of endothelial cell activation and leukocyte recruitment
during chronic inflammation that can lead to hypoxic condi-
tions, a prelude to the initiation of angiogenesis [4]. In the cur-
rent study, we show that adenoviral vectors encoding dnIκB
protein modified to selectively infect pro-angiogenic, αvβ3
integrin expressing endothelial cells can be therapeutically
exploited to inhibit TNF-α induced NF-κB activation. As a
result, mRNA levels of E-selectin, VCAM-1, ICAM-1, IL-6 and
IL-8 were reduced to basal.
In contrast to the well-acknowledged role of NF-κB in inflam-
mation [5,9-13,20], its involvement in angiogenesis has been
studied in much less detail [21,22]. Several lines of evidence
Figure 4
Inhibitory effects of αvβ3-retargeted adenovirus on tumor necrosis factor (TNF)-α induced gene expression of cell adhesion molecules, cytokines,  and angiogenesis associated molecules in human umbilical vein endothelial cells (HUVECs) Inhibitory effects of αvβ3-retargeted adenovirus on tumor necrosis factor (TNF)-α induced gene expression of cell adhesion molecules, cytokines, 
and angiogenesis associated molecules in human umbilical vein endothelial cells (HUVECs). Non-transduced (solid bar) and AddnIκB-PEG-RGD 
transduced HUVECs (open bar) with 7,500 vp/cell were activated with TNF-α (100 ng/ml) for 24 h. Real time RT-PCR was performed on mRNA iso-
lated from each respective HUVEC incubation. Data were normalized to untreated, non-activated control HUVECs arbitrarily set at 1. Results are 
expressed as the mean ± standard deviation (n = 3). Asterisks indicate p < 0.05 compared with respective control cells without activation with TNF-
α (TNF-α (-)). ICAM, intercellular adhesion molecule; nd, not detectable; ns, not significant; VCAM, vascular cell adhesion molecule; VEGF, vascular 
endothelial growth factor.Arthritis Research & Therapy    Vol 8 No 1    Ogawara et al.
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suggest a functional role for this transcription factor in capillary
tube formation [23] and retinal neovascularization [24].
Cytokines are crucial participants in receptor-mediated intrac-
ellular signaling during the (patho)physiological processes in
inflammation-associated cellular events. They affect the
endothelial cells per se by inducing the expression of a com-
plex array of genes, thereby changing the endothelial activa-
tion status and the balance between cell growth and
differentiation and cell survival and cell death [25]. Among
them, IL-6 and IL-8 are mainly produced by endothelial cells
and are critical players in the initiation phases of immunity and
inflammation. Besides its active role in inflammation, it has
recently been recognized that IL-8 also has potent pro-ang-
iogenic effects through the induction of endothelial cell prolif-
eration and capillary tube organization [26]. Thus, inhibition of
IL-8 expression is likely to have anti-angiogenic as well as anti-
inflammatory effects. The strong inhibitory effects of dnIκB
expression in endothelial cells on VEGF-A and Tie-2 gene
expression further point to the potential consequences of this
therapeutic strategy for inflammation induced angiogenesis.
Vascular smooth muscle cells can also be the source of
VEGF-A and, as such, can contribute to inflammation-induced
angiogenesis. Angiogenesis often takes place in microvascu-
lar bed endothelial cells, however, where only sparsely distrib-
uted pericytes are covering the vessel wall in these capillaries
[27]. Whether inhibition of microvascular, endothelial expres-
sion of angiogenic genes per se will suffice in counteracting
the pro-angiogenic status of the tissue will be the focus of
future in vivo pharmacological studies. An important advan-
tage of the use of PEGylated virus is that PEGylated virus
shows a significantly increased blood residence time in mice.
The area under the plasma concentration time curve value was
shown to be 17-fold increased compared to that of non-mod-
ified virus [15]. Extensive circulation ensures prolonged expo-
sure of the target endothelial cells in the inflamed joint to the
therapeutic gene vector, which may positively affect the thera-
peutic efficacy.
For selectivity of targeting, the discrimination between
endothelial cells in chronic inflammatory, angiogenic lesions
and the normal quiescent vascular endothelium is critical. In
the past years, several target epitopes over-expressed on acti-
vated (for example, angiogenic or pro-inflammatory) endothe-
lial cells have been identified, including αvβ3 integrins [28], E-
selectin [29] and VCAM-1 [30]. We previously reported that
anti-E-selectin antibody-directed PEGylated adenovirus selec-
tively homed to inflamed skin in mice with a delayed type
hypersensitivity skin inflammation. As a result, selective local
expression of the reporter transgene luciferase took place
[15]. Although E-selectin is present on endothelial cells in
inflamed joints in mice suffering from arthritis, the number of
capillaries positive for this potential target was found to be low
[31]. As is the case in tumor vasculature, heterogeneity in
endothelial activation status may also present itself during
chronic phases of inflammation. Therefore, a multi-target
approach should be considered to obtain optimal pharmaco-
logical effects.
In the present study, we demonstrated that chemically modi-
fied AddnIκB-PEG-RGD exhibited a shift in specificity of cell
entry from its intrinsic CAR-driven entry pathway to an αv
integrin-mediated pathway. Although our present study only
dealt with HUVECs, our previous study showed that the RGD-
PEG-adenovirus enabled transduction of the reporter gene
luciferase in CAR-negative but αvβ3 integrin-positive mouse
endothelial cells. Together with the observation that in the
same CAR-negative cells no luciferase activity could be trans-
duced by non-modified adenovirus, this implies that the trans-
duction by the chemically modified virus is αvβ3 integrin
specific [15]. This specificity furthermore means that in vivo,
Figure 5
AddnIκB-PEG-RGD can transduce functional dnIκB in a concentration dependent way leading to diminished intercellular adhesion molecule  (ICAM)-1 protein expression upon tumor necrosis factor (TNF)-α stimulation in human umbilical vein endothelial cells (HUVECs) as determined by  flow cytometry AddnIκB-PEG-RGD can transduce functional dnIκB in a concentration dependent way leading to diminished intercellular adhesion molecule 
(ICAM)-1 protein expression upon tumor necrosis factor (TNF)-α stimulation in human umbilical vein endothelial cells (HUVECs) as determined by 
flow cytometry. Minus and plus signs and denotes resting, non-infected, and TNF-α activated, non-infected HUVECs, respectively. All other histo-
grams represent the responses of dnIκB expressing HUVECs to TNF-α activation. The larger the number of viral particles/cell (× 103) of AddnIκB-
PEG-RGD used for the infection, the higher the percentage of ICAM-1dim cells upon TNF-α activation.Available online http://arthritis-research.com/content/8/1/R32
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αvβ3 integrin-positive cells, including angiogenic endothelial
cells, macrophages in spleen and liver, and macrophage sub-
sets in the intestines [32] and also fibroblasts and macro-
phages that constitute the synovial lining [33,34], are likely to
be the target for the modified virus. Our data also demon-
strated that our chemically modified AddnIκB-PEG-RGD can
exert pharmacological effects similar to those observed with
the non-modified virus. An interesting observation was the fact
that the amount of transgene protein required to inhibit NF-κB
dependent gene transcription was much less than the amount
of endogenous IκB present in the cells. Moreover, no linear
relationship between the amount of dnIκB expressed in
HUVECs (Figure 3) and the effect was observed (Figures 1b
and 4). A similar anomaly between the degree of inhibition of
IκB degradation and its effect on mRNA or protein expression
level for several inflammation-related markers was previously
reported by Liu and colleagues [35]. To investigate whether
the absolute amount of dnIκB to be delivered in vivo will be
sufficient to inhibit the inflammatory and/or angiogenic behav-
ior of the endothelial target cells is an important issue to
address and is the focus of future studies.
We focused our research on the delivery of therapeutic genes
into endothelial cells, yet there is now considerable evidence
in support of a role for NF-κB in synoviocyte survival as well
[36]. By combining the therapeutic approach presented here
with homing devices to, for example, target synoviocytes in the
joint [37] or cells in the neointima in artery injury [38], a range
of possibilities can be defined to explore the therapeutic ben-
efit of targeted interference with different cells actively
involved in joint destruction [39]. Since NF-κB has the dual
function of being responsible for both tissue protection and
systemic inflammation [40], targeted inhibition of NF-κB is vital
to modulate the activation status of cells involved in disease
progression while avoiding the detrimental effects of NF-κB
blockade in non-target cells.
Conclusion
RGD modification endowed PEGylated adenovirus with the
specificity of cell entry via αvβ3 integrin, thereby avoiding its
intrinsic coxsacki-adenovirus receptor controlled entry. RGD-
targeted adenovirus delivered the dnIκB via αvβ3 to become
functionally expressed leading to complete abolishment of
TNF-α-induced up-regulation of E-selectin, ICAM-1, VCAM-1,
IL-6, IL-8, VEGF-A and Tie-2 in HUVECs. The approach of tar-
geted delivery of dnIκB into endothelial cells presented here
can be employed for diseases such as rheumatoid arthritis and
inflammatory bowel disease where activation of NF-κB activity
should be locally restored to basal levels in the endothelium.
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